# Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

> **NCT00721279** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 549 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Sifrol® (pramipexole dihydrochloride)

## Key facts

- **NCT ID:** NCT00721279
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2014-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721279, "Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00721279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*